PTIE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pain Therapeutics Inc's revenue for the three months ended in Sep. 2014 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2014 was $35.24 Mil. Pain Therapeutics Inc's revenue per share for the three months ended in Sep. 2014 was $0.00. Its revenue per share for the trailing twelve months (TTM) ended in Sep. 2014 was $0.77.
During the past 12 months, the average Revenue per Share Growth Rate of Pain Therapeutics Inc was 352.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 32.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.80% per year.
During the past 13 years, Pain Therapeutics Inc's highest 3-Year average Revenue per Share Growth Rate was 129.50% per year. The lowest was 0.00% per year. And the median was -21.80% per year.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Pain Therapeutics Inc Revenue for the trailing twelve months (TTM) ended in Sep. 2014 was 35.244 (Dec. 2013 ) + 0 (Mar. 2014 ) + 0 (Jun. 2014 ) + 0 (Sep. 2014 ) = $35.24 Mil.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Pain Therapeutics Inc Annual Data
Pain Therapeutics Inc Quarterly Data